HealthEquity, Inc. (NASDAQ:HQY) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC trimmed its stake in HealthEquity, Inc. (NASDAQ:HQY) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 870,735 shares of the company’s stock after selling 5,613 shares during the quarter. Geneva Capital Management LLC owned approximately 1.01% of HealthEquity worth $57,730,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. McGlone Suttner Wealth Management Inc. purchased a new stake in HealthEquity in the 4th quarter valued at about $29,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of HealthEquity during the 3rd quarter valued at $41,000. Fifth Third Bancorp increased its holdings in shares of HealthEquity by 36.5% during the 3rd quarter. Fifth Third Bancorp now owns 602 shares of the company’s stock worth $44,000 after buying an additional 161 shares during the last quarter. Operose Advisors LLC purchased a new position in shares of HealthEquity in the 3rd quarter worth $44,000. Finally, Covestor Ltd raised its position in shares of HealthEquity by 92.9% in the 3rd quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $82,000 after buying an additional 539 shares during the period. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

HealthEquity Stock Performance

Shares of NASDAQ:HQY traded down $0.56 during trading on Thursday, reaching $77.45. 794,378 shares of the company’s stock traded hands, compared to its average volume of 595,660. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76. The company has a 50 day moving average of $80.56 and a 200-day moving average of $74.75. HealthEquity, Inc. has a 12 month low of $53.58 and a 12 month high of $84.49. The stock has a market capitalization of $6.65 billion, a P/E ratio of 121.63, a price-to-earnings-growth ratio of 1.28 and a beta of 0.55.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.08. The business had revenue of $262.39 million for the quarter, compared to the consensus estimate of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. On average, equities analysts expect that HealthEquity, Inc. will post 2.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HQY. JPMorgan Chase & Co. upped their price target on HealthEquity from $86.00 to $108.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Bank of America lifted their price target on shares of HealthEquity from $93.00 to $97.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Royal Bank of Canada increased their price objective on shares of HealthEquity from $90.00 to $92.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 20th. KeyCorp lifted their target price on shares of HealthEquity from $85.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Finally, JMP Securities began coverage on HealthEquity in a report on Thursday, April 4th. They issued a “mkt outperform” rating and a $101.00 price target for the company. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.17.

Insider Transactions at HealthEquity

In related news, Director Evelyn S. Dilsaver sold 32,500 shares of HealthEquity stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total value of $2,576,925.00. Following the sale, the director now directly owns 32,123 shares in the company, valued at approximately $2,547,032.67. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other HealthEquity news, Director Evelyn S. Dilsaver sold 32,500 shares of HealthEquity stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the sale, the director now owns 32,123 shares of the company’s stock, valued at approximately $2,547,032.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Delano Ladd sold 2,499 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $80.00, for a total value of $199,920.00. Following the transaction, the executive vice president now owns 49,996 shares of the company’s stock, valued at approximately $3,999,680. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,322 shares of company stock worth $5,682,895. Insiders own 2.70% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.